The German Competence Network on Atrial Fibrillation (AFNET)

被引：12

作者：

Breithardt, Guenter ^{[1
,10
]}

Dobrev, Dobromir ^{[2
,10
]}

Doll, Nicolas ^{[3
,10
]}

Goette, Andreas ^{[4
,10
]}

Hoffmann, Boris ^{[5
,10
]}

Kirchhof, Paulus ^{[1
,10
]}

Koester, Ilka ^{[6
,10
]}

Kuck, Karl-Heinz ^{[6
,10
]}

Leute, Angelika ^{[10
]}

Meinertz, Thomas ^{[5
,10
]}

Naebauer, Michael ^{[7
,10
]}

Oeff, Michael ^{[8
,10
]}

Ravens, Ursula ^{[2
,10
]}

Schuchert, Andreas ^{[9
,10
]}

Sprenger, Claudia ^{[8
,10
]}

Steinbeck, Gerhard ^{[7
,10
]}

Willems, Stephan ^{[5
,10
]}

机构：

[1] Univ Hosp, Dept Med Cardiol & Angiol C, Munster, Germany

[2] Tech Univ Dresden, Dept Pharmacol & Toxicol, Dresden, Germany

[3] Sana Herzchirurg Stuttgart GmbH, Stuttgart, Germany

[4] Univ Magdeburg, Dept Cardiol Angiol & Pneumol, D-39106 Magdeburg, Germany

[5] Univ Herzzentrum gGmbH, Dept Cardiol Angiol, Hamburg, Germany

[6] Asklepios Klin St Georg, Hamburg, Germany

[7] Univ Hosp Grosshadern, Dept Med 1, Munich, Germany

[8] Municipal Hosp, Dept Internal Med 1, Brandenburg, Germany

[9] Friedrich Ebert Krankenhaus GmbH, Dept Med, Neumunster, Germany

[10] Univ Hosp, Competence Network Atrial Fibrillat, Munster, Germany

来源：

HERZ | 2008年 / 33卷 / 08期

关键词：

Atrial fibrillation (AF); Atrial remodeling; Antiarrhythmic drugs; Cardioversion; Pulmonary vein isolation; Ablation; Preventive pacing;

D O I：

10.1007/s00059-008-3177-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The German Competence Network on Atrial Fibrillation (AFNET) is an interdisciplinary national research network funded by the Federal Ministry of Education and Research (BMBF) since 2003. The AFNET aims at improving treatment of atrial fibrillation (AF), the most frequent sustained arrhythmia of the heart. The AFNET has established a nationwide patient registry on manifestation, diagnostics, and therapy of AF in Germany. The data analyzed to date demonstrate that patients with AF are likely to have multiple comorbidities (hypertension, valvular heart disease, coronary artery disease, diabetes mellitus) and an advanced age. Regarding oral anticoagulation, guideline adherence is very high. Basic research has identified specific changes in atrial tissue during AF-induced remodeling providing the rationale for novel therapeutic interventions. Clinical trials are being carried out to optimize pharmacological and nonpharmacological treatments. The ANTI-PAF trial is designed to prove that angiotensin II receptor blockers reduce the incidence of paroxysmal AF. The Flec-SL trial tests the efficacy of a short-term treatment with antiarrhythmic drugs after cardioversion. The Gap-AF trial investigates the impact of complete pulmonary vein (PV) isolation versus incomplete circumferential PV ablation on AF recurrences. The effect of preventive pacing on the recurrence of paroxysmal AF is studied in the BACE-PACE trial.

引用

页码：548 / 555

页数：8

共 25 条

[21]

Pappone C, 2000, CIRCULATION, V102, pE123

[22] A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community - The Framingham Heart Study [J].

Wang, TJ ;

Massaro, JM ;

Levy, D ;

Vasan, RS ;

Wolf, PA ;

D'Agostino, RB ;

Larson, MG ;

Kannel, WB ;

Benjamin, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (08) :1049-1056

[23] Increased atrial fibrillation mortality: United States, 1980-1998 [J].

Wattigney, WA ;

Mensah, GA ;

Croft, JB .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (09) :819-826

[24] ATRIAL-FIBRILLATION AS AN INDEPENDENT RISK FACTOR FOR STROKE - THE FRAMINGHAM-STUDY [J].

WOLF, PA ;

ABBOTT, RD ;

KANNEL, WB .

STROKE, 1991, 22 (08) :983-988

[25]

ZELLERHOFF S, 2008, J CARDIOVAS IN PRESS

← 1 2 3 →